A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123.
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2016
At a glance
- Drugs Sunitinib (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer
- Focus Biomarker; Therapeutic Use
- 11 Apr 2011 Planned end date changed from Oct 2011 to Apr 2011 as reported by ClinicalTrials.gov.
- 11 Apr 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 16 Feb 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.